MAIA Biotechnology (MAIA) Cash from Financing Activities (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Cash from Financing Activities for 6 consecutive years, with $31.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 468.6% year-over-year to $31.1 million; the TTM figure through Mar 2026 stood at $43.5 million (up 129.89% YoY), while the FY2025 annual figure was $17.9 million, down 1.49% from the prior year.
• Cash from Financing Activities grew to $31.1 million in Q1 2026 per MAIA's latest filing, from $4.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $31.1 million in Q1 2026 and bottomed at -$192905.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $5.7 million across 5 years, with a median of $4.7 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 115.7% — and 2023, when it jumped 2705.14%.
• MAIA Biotechnology's Cash from Financing Activities stood at -$192905.0 in 2022, then surged by 2705.14% to $5.0 million in 2023, then dropped by 3.58% to $4.8 million in 2024, then slipped by 0.89% to $4.8 million in 2025, then jumped by 546.6% to $31.1 million in 2026.
• Business Quant data shows MAIA's Cash from Financing Activities at $31.1 million in Q1 2026, $4.8 million in Q4 2025, and $4.2 million in Q3 2025.